August 8, 2014
Sumitomo Dainippon President Masayo Tada Sumitomo Dainippon Pharma may need to revise its FY2013-FY2017 midterm business plan due to the termination of a global PIII study of its colorectal cancer drug BBI608, the president said on August 7. Last year,...read more